Medexus Pharmaceuticals Inc. (TSE:MDP) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Medexus Pharmaceuticals Inc. has received a consensus rating of "Buy" from seven research firms, with four issuing a strong buy rating.
• The average one-year target price for Medexus shares is C$5.49, with the stock currently trading at approximately C$3.08.
• Medexus specializes in treatments for autoimmune diseases and pediatrics, featuring products like Rasuvo and Rupall.

Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is C$5.49.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th.

Medexus Pharmaceuticals Stock Performance

TSE MDP opened at C$3.08 on Friday. The company has a market capitalization of C$99.35 million, a P/E ratio of 154.00 and a beta of 2.55. The stock has a 50 day moving average price of C$2.89 and a 200-day moving average price of C$2.76. Medexus Pharmaceuticals has a one year low of C$1.71 and a one year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.